ABL1 and non-small cell lung carcinoma: Despite the excellent finding of tyrosine kinase-targeted therapy for cancer treatment, such as imatinib for CML with BCR/ABL [21] or erlotinib for non-small-cell lung carcinoma [22], the resistance to the treatment still remains a difficult problem and there is a need to overcome it to get better healthcare.